At this point, recommendations by the American College of Rheumatology/Arthritis Foundation Guidelines (ACR/AFG) suggest initiating therapy with a monoclonal antibody TNF-alpha inhibitor such as ADA [3]. Here, TNF is linked to arthritic joint disease.